Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer

Journal of Molecular Medicine

Volumn 90, Issue 10, 2012, Pages 1121-1132

  Ren, Shancheng ^a   Xu, Chuanliang ^a   Cui, Zilian ^a   Yu, Yongwei ^a   Xu, Weidong ^a   Wang, Fubo ^a   Lu, Ji ^a   Wei, Min ^a   Lu, Xin ^a   Gao, Xu ^a   Liang, You ^b   Mao, Jian Hua ^c   Sun, Yinghao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Cereblon; CUL4A; Prostate cancer; Thalidomide; Translational research

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; THALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CUL4A GENE; DOWN REGULATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO CULTURE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATE EPITHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CULLIN PROTEINS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PEPTIDE HYDROLASES; PROSTATIC NEOPLASMS; RNA INTERFERENCE; THALIDOMIDE; TISSUE ARRAY ANALYSIS; TUMOR BURDEN;

EID: 84867331145     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-012-0885-0     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
2. Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24:1967-2000
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
5. Bartlett JB, Dredge K, Dalgleish AG (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4:314-322
6. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24:22-32
7. Dauguet N, Fournie JJ, Poupot R, Poupot M (2010) Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human natural killer cells. Cell Immunol 264:163-170
8. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K et al (2010) Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): a Gynecologic Oncology Group Study. Gynecol Oncol 119:444-450
9. Reiriz AB, Richter MF, Fernandes S, Cancela AI, Costa TD, Di Leone LP, Schwartsmann G (2004) Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res 14:527-531
10. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG (2009) Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 73:337-341
11. Dal Lago L, Richter MF, Cancela AI, Fernandes SA, Jung KT, Rodrigues AC, Costa TD, Di Leone LP, Schwartsmann G (2003) Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. Invest New Drugs 21:359-366
12. Burris HA 3rd, Jones SF, Shipley D, Meluch AA, Greco FA, Barton JH, Yardley DA, Hainsworth JD (2010) Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. Cancer Invest 28:408-412
13. Lee SM, Rudd R, Woll PJ, Ottensmeier C, Gilligan D, Price A, Spiro S, Gower N, Jitlal M, Hackshaw A (2009) Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:5248-5254
14. Pacheco AV, Rasila K, Lee SJ, Rabinowitz I, Elias L, Lee FC, Verschraegen CF (2008) Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols. Urol Oncol 26:610-615
15. Boyd KD, Walker BA, Wardell CP, Ross FM, Gregory WM, Davies FE, Morgan GJ (2010) High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leukemia Lymphoma 51:2126-2129
16. Bagratuni T, Wu P, Gonzalez de Castro D, Davenport EL, Dickens NJ, Walker BA, Boyd K, Johnson DC, Gregory W, Morgan GJ et al (2010) XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomidebased treatments. Blood 116:250-253
17. Brenne AT, Romstad LH, Gimsing P, Juliusson G, Turesson I, Romundstad P, Borset M, Sundan A, Waage A (2004) A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma. Haematologica 89:552-556
18. Nishitani H, Shiomi Y, Iida H, Michishita M, Takami T, Tsurimoto T (2008) CDK inhibitor p21 is degraded by a proliferating cell nuclear antigen-coupled Cul4-DDB1Cdt2 pathway during S phase and after UV irradiation. J Biol Chem 283:29045-29052
19. Li B, Jia N, Kapur R, Chun KT (2006) Cul4A targets p27 for degradation and regulates proliferation, cell cycle exit, and differentiation during erythropoiesis. Blood 107:4291-4299
20. Li J, Wang QE, Zhu Q, El-Mahdy MA, Wani G, Praetorius-Ibba M, Wani AA (2006) DNA damage binding protein component DDB1 participates in nucleotide excision repair through DDB2 DNA-binding and cullin 4A ubiquitin ligase activity. Cancer Res 66:8590-8597
21. Nag A, Bagchi S, Raychaudhuri P (2004) Cul4A physically associates with MDM2 and participates in the proteolysis of p53. Cancer Res 64:8152-8155
22. Chen LC, Manjeshwar S, Lu Y, Moore D, Ljung BM, Kuo WL, Dairkee SH, Wernick M, Collins C, Smith HS (1998) The human homologue for the Caenorhabditis elegans cul-4 gene is amplified and overexpressed in primary breast cancers. Cancer Res 58:3677-3683
23. Melchor L, Saucedo-Cuevas LP, Munoz-Repeto I, Rodriguez-Pinilla SM, Honrado E, Campoverde A, Palacios J, Nathanson KL, Garcia MJ, Benitez J (2009) Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast Cancer Res 11:R86
24. Shinomiya T, Mori T, Ariyama Y, Sakabe T, Fukuda Y, Murakami Y, Nakamura Y, Inazawa J (1999) Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon. Genes Chromosomes Cancer 24:337-344
25. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P (2000) Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Gene Chromosome Canc 28:145-152
26. Michiels EMC, Weiss MM, Hoovers JMN, Baak JPA, Voute PA, Baas F, Hermsen MAJA (2002) Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediat Hematol Onc 24:205-210
27. Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H, Emi M, Inazawa J (2002) TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 35:1476-1484
28. Schindl M, Gnant M, Schoppmann SF, Horvat R, Birner P (2007) Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer. Anticancer Res 27:949-952
29. Hung MS, Mao JH, Xu ZD, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Jablons DM, You LA (2011) Cul4A is an oncogene in malignant pleural mesothelioma. J Cell Mol Med 15:350-358
30. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S et al (2004) Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13:1303-1313
31. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H (2010) Identification of a primary target of thalidomide teratogenicity. Science 327:1345-1350
32. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS (1997) Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18:1215-1223
33. Wang H, Zhai L, Xu J, Joo HY, Jackson S, Erdjument-Bromage H, Tempst P, Xiong Y, Zhang Y (2006) Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol Cell 22:383-394
34. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S, Chang XB, Bjorklund CC, Fonseca R, Bergsagel PL et al (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118:4771-4779
35. Higa LA, Wu M, Ye T, Kobayashi R, Sun H, Zhang H (2006) CUL4-DDB1 ubiquitin ligase interacts with multipleWD40-repeat proteins and regulates histone methylation. Nat Cell Biol 8:1277-1283